Agency Business briefs

Share this article:
Omnicom's Diversified Agency Services unit has entered into a “strategic alliance agreement” with London scientific communications shop Chameleon Communications International. The deal involves collaboration on global healthcare assignments.  

Adair-Greene McCann landed an assignment for the launch of a Philips/Respironics device called SleepWave, for the treatment of insomnia. The Atlanta-based shop handled marketing and advertising materials for the launch of the device in Australia, the first country in a planned global roll-out.  

StrikeForce Communications won the assignments for Alcon's I-CAPS ocular nutrition franchise, designed to delay the progress of age-related macular degeneration, and Systane OTC dry eye therapy. The agency also won the launch assignment for an experimental obesity drug from San Diego-based Orexigen Therapeutics.

Martino Flynn, an agency based in Rochester, NY, launched a healthcare practice aimed at OTC products and medical devices. The shop, which offers PR, digital and advertising services, has worked on brands including Ace, Anacin, Delsym, Dermarest, Gentle Naturals and Sucrets.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?